INTRODUCTION: Diabetes mellitus (DM) is a chronic disease characterized by hyperglycemia, and its prevalence is rapidly increasing in the whole world. Preptin is a novel molecule playing role in metabolic pathways which is secreted along with insulin from the pancreatic beta cells and there are limited number of studies about preptin in patients with type 2 DM (T2DM). This study was designed to observe how plasma preptin levels change in patients with T2DM in comparison to control group.
METHODS: The study included 82 patients with T2DM (mean age: 49.00±5.97 years, 42 females/40 males) and 65 healthy individuals (mean age: 41.98±5.62 years, 31 females/34 males). Patients with T2DM were divided into two groups as newly-diagnosed and previously diagnosed-having treatment. Those previously-diagnosed-having treatment group were further divided into two groups based on their HbA1c levels as well-controlled DM (HbA1C value<7%) and poorly-controlled DM (HbA1C value>7%). Chemistry parameters were analyzed with Advia 1800 analyzer, whereas hormonal parameters were analyzed with Immulite-2000 analyzer. Plasma preptin levels were measured via ELISA method.
RESULTS: Patients with newly or previously-diagnosed-having treatment group T2DM had significantly higher levels of glucose, HbA1c, insulin, HOMA-IR, total cholesterol, triglyceride, LDL-cholesterol and preptin (for each p<0.001), and significantly lower HDL-cholesterol levels compared to the control group (p<0.001). Preptin levels showed positive correlation with insulin, HOMA-IR, HbA1c and glucose levels (for control group: r=0.452-p=0.000, r=0.472-p=0.000, r=0.389-p=0.001, r=0.286-p=0.021, respectively; for T2DM group: r=0.484-p=0.000, r=0.544-p=0.000, r=0.288-p=0.009, r=0.236-p=0.033, respectively).
DISCUSSION AND CONCLUSION: The observed correlation between preptin levels and diabetes suggests possible role of this peptide in the pathogenesis of DM, which is a major public health problem.